Clinical trials: Primary Parkinsonism
Parkinson Disease
Developing Personalized Medicine Strategies to Increase Physical Activity in Parkinson's Disease (PD) Through Digital Health Technology
Under a grant from the Department of Defense's PD program, Dr. Morley's is investigating new approaches that 1) use "gamification"- applying rules of games like point scoring, achieving silver, gold or platinum levels and…
- Trial name
- NCT05529121
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Parkinson Disease
Protocol: Balance Training in Parkinson's Disease
Postural instability is a particularly incapacitating disorder, where loss of motor independence by Parkinson´s Disease (PD) patients marks a significant stage of disease onset.
- Trial name
- NCT02488265
- Testing
- Balance Training, Screening to prevent falls
- Where
- Brazil
- Volunteers
- 150 people
- Sponsor
- University of Sao Paulo General Hospital
Early Onset Parkinson Disease, Early Stage Parkinson Disease
Dual-task Performance in Young-onset PD
This study aimed to investigate the effects of Game based dual-task training with treadmill on executive function and dual-task performance in individuals with early-onset PD and discuss the correlation between the change values…
- Trial name
- NCT04033393
- Testing
- Game based dual-task training, Treadmill training
- Volunteers
- 40 people
- Sponsor
- National Yang Ming Chiao Tung University
Parkinson Disease, Brain Stimulation
Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder and affects approximately 1 million people in the United States with total annual costs approaching 11 billion dollars.
- Conditions
- Parkinson Disease, Brain Stimulation, Cerebellum
- Trial name
- NCT04046055
- Testing
- Transcranial direct current stimulation at 2 mA, Transcranial direct current stimulation at 4 mA
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Thorsten Rudroff
Parkinson Disease, Parkinsons Disease With Dementia
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder causing motor and non-motor symptoms. PD is characterized by death of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta and…
- Trial name
- PD Nilotinib (NCT02954978)
- Testing
- Nilotinib 150mg oral capsule [Tasigna], Nilotinib 300mg oral capsule [Tasigna]
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Georgetown University
Hallucinations, Psychoses
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis.
- Conditions
- Hallucinations, Psychoses, Parkinson's Disease
- Trial name
- NCT00087542
- Testing
- ACP-103
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson Disease, Weight-Lifting Exercise Program
Training and Parkinson's
The purpose of the current study is to compare the impacts of specifically designed power training and strength training programs on function and physical performance in Parkinson's patients.
- Trial name
- NCT03434327
- Testing
- Strength Training, Power Training
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Miami
Mild Cognitive Impairment, Parkinson Disease
Effects of Physical-Cognitive Training With Different Task Models in Parkinson's Disease With Mild Cognitive Impairment
The present study will characterize exercise model effects (integrated model vs. consecutive model) of physical-cognitive exercise on dual-task walking control in Parkinson's disease with mild cognitive impairment.
- Trial name
- NCT05172661
- Testing
- Integrated physical-cognitive training, Consecutive physical-cognitive training
- Where
- Taiwan
- Volunteers
- 27 people
- Sponsor
- National Taiwan University Hospital
Parkinson's Disease, Depression
Long Term Follow Up KET-PD
The purpose of this study is to examine a) the longer-term effects of ketamine for treating depression in Parkinson's disease (PD) and b) the effects of CBT on maintaining the effects of ketamine.
- Trial name
- NCT06164756
- Testing
- Cognitive Behavior Therapy (CBT), Treatment As Usual (TAU)
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Yale University
Dystonia-Parkinsonism, Adult-Onset, Parkinson Disease
Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
This study occurs during five visits that are already scheduled as part of "Biomarkers to Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688).
- Trial name
- NCT03409120
- Testing
- Boston Scientific Vercise PC IPG with directional DBS lead
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Alabama at Birmingham
Parkinson Disease(PD)
Adaptive DBS for PD
The goal of this clinical trial is to evaluate the efficacy and safety of an adaptive deep brain stimulation (aDBS) system for managing Parkinson's disease symptoms.
- Trial name
- SMART-DBS (NCT07635823)
- Testing
- adaptive deep brain stimulation, conventional deep brain stimulation
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Parkinson's Disease
Selegiline to Zelapar Switch Study in Parkinson Disease Patients
Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain.
- Trial name
- NCT00640159
- Testing
- Zelapar
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Baylor College of Medicine
Parkinson Disease
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinson's Disease in 14 weeks of treatment, and to investigate the safety and tolerability of NS 2330 in these patients.
- Trial name
- NCT00148486
- Testing
- NS 2330
- Where
- 55 sites in United States, Canada
- Volunteers
- 261 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Comparison of Different Rehabilitation Protocols in Parkinson's Disease With Postural Instability and Gait Disorders
The aim of the study is to compare the effects of 2 different dosages and modalities of motor-cognitive rehabilitation in Parkinson's disease with postural instability and gait disorders (PD-PIGD) on clinical features…
- Trial name
- NCT05799690
- Testing
- Gait and balance training with dual-task + action observation and motor imagery (six weeks), Gait and balance training with dual-task (six weeks), Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6)
- Where
- 2 sites in Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Prof. Massimo Filippi
Parkinson Disease
Constipation and Changes in the Gut Flora in Parkinson's Disease
The aim of this study is to investigate the link between gut health and Parkinson's disease
- Trial name
- GUT-PD (NCT05787756)
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen
Parkinson Disease
N-Acetylcysteine for Neuroprotection in Parkinson's Disease
The overall objective of this developmental/exploratory study is to use noninvasive proton magnetic resonance spectroscopy (1H MRS) to assess (a) whether brain levels of the antioxidant glutathione (GSH) are decreased in vivo, as…
- Trial name
- NAC for PD (NCT01470027)
- Testing
- N-acetylcysteine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Parkinson's Disease (PD)
Electrophysiology-based DBS Programming for PD
Deep brain stimulation (DBS) effectively alleviates motor symptoms in Parkinson's disease (PD). However, current programming is manual and time-consuming.
- Trial name
- NCT07348705
- Testing
- Clinician-based DBS programming, Maximum Beta power-based DBS programming, Broad-band electrophysiology-based DBS programming
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Parkinson Disease, Multiple System Atrophy
Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.
Parkinson disease (PD) and multiple system atrophy (MSA) are progressive neurodegenerative disorders characterized by abnormal accumulation of α-synuclein.
- Trial name
- NCT02064166
- Testing
- Intranasal Insulin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Peter Novak
Parkinson Disease, Tremor, Essential
Effectiveness and Reliability of Hypnosis in Stereotaxy
In certain neurosurgical procedures, the use of a stereotaxic frame is required. It is then possible to set a precise target (depending of the type of the surgery) to be reached by the surgeon.
- Conditions
- Parkinson Disease, Tremor, Essential, Dystonia, Primary
- Trial name
- ERST (NCT03074422)
- Testing
- Hypnosis
- Where
- Switzerland
- Volunteers
- 22 people
- Sponsor
- University Hospital, Geneva
Parkinson Disease
Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease
This is a multi-center, open-label, single-arm 8-week investigation of Selegiline for treatment of EDS in PD patients.
- Trial name
- NCT04870372
- Testing
- Selegiline
- Where
- 4 sites in China
- Volunteers
- 141 people
- Sponsor
- Second Affiliated Hospital of Soochow University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.